Timothy D Carroll1,2, Sinthujan Jegaskanda3, Shannon R Matzinger1,2, Linda Fritts1,2, Michael B McChesney2, Stephen J Kent3,4,5, Jeffery Fairman6, Christopher J Miller1,2,7. 1. Center for Comparative Medicine, University of California, Davis. 2. California National Primate Research Center, University of California, Davis. 3. Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University. 4. Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity. 5. Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Australia. 6. Colby Pharmaceutical Company, Menlo Park. 7. Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis.
Abstract
Background: Influenza A virus (IAV) vaccines offer little protection from mismatched viruses with antigenically distant hemagglutinin (HA) glycoproteins. We sought to determine if a cationic lipid/DNA complex (CLDC) adjuvant could induce heterosubtypic protection if added to a whole inactivated IAV vaccine (WIV). Methods: Adult rhesus macaques (RMs) were vaccinated and at 2 weeks boosted with either an H1N1-WIV or an H3N2-WIV, with and without CLDC adjuvant. Four weeks postboost, animals were challenged with an H1N1 IAV matched to the H1N1-WIV vaccine. Results: After challenge, viral RNA (vRNA) levels in the trachea of control RMs and RMs vaccinated with the unadjuvanted H1 or H3 WIV vaccines were similar. However, vRNA levels in the trachea of both the H1-WIV/CLDC- and the H3-WIV/CLDC-vaccinated RMs (P < 0.01 and P < 0.05, respectively) were significantly lower than in unvaccinated control RMs. Heterosubtypic protection in H3-WIV/CLDC RMs was associated with significantly higher levels of nucleoprotein (NP) and matrix-1-specific immunoglobulin G antibodies (P < 0.05) and NP-specific nonneutralizing antibody-dependent natural killer cell activation (P < 0.01) compared with unprotected H3-WIV RMs. Conclusions: Addition of the CLDC adjuvant to a simple WIV elicited immunity to conserved virus structural proteins in RMs that correlate with protection from uncontrolled virus replication after heterosubtypic influenza virus challenge.
Background: Influenza A virus (IAV) vaccines offer little protection from mismatched viruses with antigenically distant hemagglutinin (HA) glycoproteins. We sought to determine if a cationic lipid/DNA complex (CLDC) adjuvant could induce heterosubtypic protection if added to a whole inactivated IAV vaccine (WIV). Methods: Adult rhesus macaques (RMs) were vaccinated and at 2 weeks boosted with either an H1N1-WIV or an H3N2-WIV, with and without CLDC adjuvant. Four weeks postboost, animals were challenged with an H1N1IAV matched to the H1N1-WIV vaccine. Results: After challenge, viral RNA (vRNA) levels in the trachea of control RMs and RMs vaccinated with the unadjuvanted H1 or H3 WIV vaccines were similar. However, vRNA levels in the trachea of both the H1-WIV/CLDC- and the H3-WIV/CLDC-vaccinated RMs (P < 0.01 and P < 0.05, respectively) were significantly lower than in unvaccinated control RMs. Heterosubtypic protection in H3-WIV/CLDCRMs was associated with significantly higher levels of nucleoprotein (NP) and matrix-1-specific immunoglobulin G antibodies (P < 0.05) and NP-specific nonneutralizing antibody-dependent natural killer cell activation (P < 0.01) compared with unprotected H3-WIV RMs. Conclusions: Addition of the CLDC adjuvant to a simple WIV elicited immunity to conserved virus structural proteins in RMs that correlate with protection from uncontrolled virus replication after heterosubtypic influenza virus challenge.
Authors: Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw Journal: Vaccine Date: 2011-05-30 Impact factor: 3.641
Authors: David K Hong; Stella Chang; Crystal M Botham; Thierry D Giffon; Jeffery Fairman; David B Lewis Journal: J Virol Date: 2010-10-13 Impact factor: 5.103
Authors: Jesse D Deere; Timothy D Carroll; Joseph Dutra; Linda Fritts; Rebecca Lee Sammak; JoAnn L Yee; Katherine J Olstad; J Rachel Reader; Amy Kistler; Jack Kamm; Clara Di Germanio; Yashavanth Shaan Lakshmanappa; Sonny R Elizaldi; Jamin W Roh; Graham Simmons; Jennifer Watanabe; Rachel E Pollard; Jodie Usachenko; Ramya Immareddy; Brian A Schmidt; Shelby L O'Connor; Joseph DeRisi; Michael P Busch; Smita S Iyer; Koen K A Van Rompay; Dennis J Hartigan-O'Connor; Christopher J Miller Journal: Microbiol Spectr Date: 2021-11-24
Authors: Wei Dong; Yoshita Bhide; Federica Sicca; Tjarko Meijerhof; Kate Guilfoyle; Othmar G Engelhardt; Louis Boon; Cornelis A M de Haan; George Carnell; Nigel Temperton; Jacqueline de Vries-Idema; David Kelvin; Anke Huckriede Journal: Front Immunol Date: 2018-10-09 Impact factor: 7.561
Authors: Michael Lim; Abu Zayed Md Badruddoza; Jannatul Firdous; Mohammad Azad; Adnan Mannan; Taslim Ahmed Al-Hilal; Chong-Su Cho; Mohammad Ariful Islam Journal: Pharmaceutics Date: 2020-01-01 Impact factor: 6.321